Aclacinomycin A in the treatment of multiple myeloma: A Southwest Oncology Group study by Karanes, Chatchada et al.
Investigational New Drugs 8: 101-104, 1990. 
9 1990 Kluwer Academic Publishers. Printed in the Netherlands. 
Aclacinomycin A in the treatment of multiple myeloma: 
A Southwest Oncology Group Study 
Chatchada Karanes l, John Crowley 2, Laxmidas Sawkar 3, Bill L. Tranum 4, William J. Hicks 5, John D. 
Bonnet 6, Lyubica Dabich 7, Bruce W. Dana 8 and Sydney Salmon 9 
1 Wayne State University School o f  Medicine; 2Southwest Oncology Group Biostatistical Center-Seattle; 
3Midwest CCOP; 4Arkansas CCOP; 5 Columbus CCOP; 6Scott and White Clinic; 7 University o f  Michigan 
Medical Center; s University o f  Oregon Health Science Center," 9 University o f  Arizona Cancer Center, USA 
Key words: Aclacinomycin A, multiple myeloma 
Summary 
Fifty-two patients with progressive resistant multiple myeloma were entered in this Southwest Oncology 
Group Phase II study, using weekly intravenous Aclacinomycin A. Of forty-three evaluable patients for 
response, there was one partial remission of 2 years duration and two sustained clinical improvements with 
25~ reduction in paraprotein. Major toxicity seen was severe myelosuppression and significant nausea and 
vomiting requiring dose reduction and delay of the scheduled treatment. Cardiac arrhythmia was seen in one 
patient. Chronic daily schedule or continuous IV infusion is recommended for future study. 
Introduction Patients and methods 
Since the introduction of doxorubicin ten years 
ago, other new agents have only played a minor role 
in the treatment of refractory multiple myeloma. 
The natural and recombinant alpha-interferons 
have shown activity in refractory myeloma, but 
their precise role in the management of this subset 
of patients is as yet unclear [1]. 
Recent phase II studies using Aclacinomycin A, 
a new anthracycline antibiotic analog of doxorubi- 
cin, have shown significant antitumor effects in 
breast, ovarian, lung, and bladder cancers and in 
malignant lymphoma. A low incidence of cardio- 
toxicity and alopecia has been demonstrated [2]. 
Based on a report of 6 out of 9 responses of myelo- 
ma to Aclacinomycin A [3], the Southwest Oncolo- 
gy Group initiated a phase II trial to determine the 
antitumor activity of this agent in refractory myelo- 
m a .  
Fifty-two patients were registered. All had histolog- 
ically confirmed multiple myeloma with progres- 
sive resistant disease, and had measurable disease, 
based on a monoclonal immunoglobulin spike in 
the serum and/or Bence-Jones proteinuria quanti- 
tated by urine electrophoresis. Prior treatment in- 
cluded alkylating agents, vincristine, nitrosourea 
and prednisone. Forty-two patients (80%) received 
doxorubicin. Pretreatment patient characteristics 
are presented in Table 1. Seventy-five percent of the 
patients had a Karnofsky performance status _> 50. 
Treatment plan 
This clinical trial was approved by the human ex- 
perimentation committee within each institution 
and all patients agreed to participate in writing. 
Aclacinomycin A was provided by the Investiga- 
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Table 1. Pretreatment patient characteristics 
Characteristics Patients (n = 52) 
Sex (M/F) 31/21 
Performance status (Karnovsky) 
90-100 4 (8O7o) 
70-80 15 (29~ 
50-60 20 (38~ 
30-40 13 (25O/o) 
Type of multiple myeloma 
lgG 25 (48%) 
IgA 17 (32o7o) 
IgD 2 (4%) 
Light chain 8 (16~ 
Prior adriamycin 
yes 42 (80~ 
no 10 (20o70) 
Response criteria 
Complete response was defined as 1) a sustained 
decrease in a monoclonal peak of more than 75% 
of the initial value or 2) a quantitative light chain in 
the urine less than 10% of the pretreatment value or 
< 200 mg/24 hours for greater than 4 weeks. Par- 
tial response was defined as a 50 -75% decline in 
the monoclonal peak or 10-50% of the pretreat- 
ment urine light chain. The response was consi- 
dered " improved"  if there was 25 -50% reduction 
in the monoclonal peak or 50 -75% of the pretreat- 
ment urine light chain. No response was defined as 
75-100% of  the pretreatment urine light chain or 
less than 25 % reduction in cell mass after receiving 
at least two courses of Aclacinomycin A treatment. 
tional Drug Branch of the National Cancer Insti- 
tute, Bethesda, Maryland. Aclacinomycin A was 
administered at an initial dose of 65 mg/m 2 by in- 
travenous infusion over 20-30  minutes. Therapy 
was given weekly for four weeks, followed by a two 
week rest period. The initial dose and schedule was 
chosen based on our previous experience from a 
phase I study [4], which would be more practical to 
give on an out-patient basis rather than a daily in- 
travenous schedule. Originally, if granulocyte 
count dropped below 1500 or platelets were less 
than 75,000, the subsequent weekly doses of 
Aclacinomycin A were decreased to 45 and 25 rag/ 
m 2, respectively. Therapy was postponed for PMN 
< 500 or platelets below 50,000. However, due to 
significant myelosuppression in the first twenty-one 
patients treated, the starting dose for the next thirty 
patients was decreased to 50 mg/m 2. The subse- 
quent dosage was reduced to 35 mg/m 2 if PMN 
was below 1000 or platelets < 75,000. Therapy was 
continued until there was evidence of progression 
of disease. 
While on therapy, CBC and serum chemistry 
were monitored once a week and every four weeks 
respectively. EKG, MUGA scan or echocardiogram 




Fifty-two patients were registered in this Southwest 
Oncology Group Phase II trial. Forty-three of these 
patients were fully evaluable for response to treat- 
ment after receiving four full doses. Forty-seven 
patients were evaluable for toxicity and five pa- 
tients were considered non-evaluable because of 
early death (i.e. within the first month of  Aclacino- 
mycin therapy). 
Response data 
Of the forty-three fully evaluable patients for re- 
sponse, only one achieved a partial remission with 
aclacinomycin therapy. This was a 65 year old black 
female who had stage III lambda light chain myelo- 
ma, initially presenting with T8 cord compression. 
A two year complete remission was obtained after 
therapy with melphalan, cyclophosphamide, vin- 
cristine, and prednisone alternating with doxorubi- 
cin, BCNU, vincristine and prednisone. At the time 
of recurrence, she had 2.9 grams of  urine lambda 
light chain in 24 hours. The daily urine light chain 
dropped to 1.1 grams after 6 months of treatment 
which subsequently decreased below 500 rag/24 
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Fig. 1. The level of urinary light chain concentration in response 
to Aclacinomycin therapy. 
hours and maintained at that level for the next 2 
years while continuing on the same therapy (Fig. 
1). Repeated MUGA scan during this time show- 
ed no changes in her left ventricular function. 
The patient received a total of 22 courses of acla- 
cinomycin over a 32 month period. The disease 
recurred 4 months after discontinuation of treat- 
ment and responded again to combination chemo- 
therapy of cyclophosphamide, melphalan and 
prednisone. She is currently doing well on therapy. 
Two additional patients considered " improved"  
had achieved 25~ reduction in serum M-com- 
ponent concentrations and marked reduction in 
bone pain with improvement of anemia and perfor- 
mance status. Of the remaining for patients, twelve 
patients showed no progression while on therapy, 
twenty-eight showed evidence of progressive dis- 
ease. 
One of the three partially evaluable patients had 
30~ reduction of serum IgG monoclonal peak af- 
ter 3 weekly doses, but the therapy was discon- 
tinued due to intractable nausea and vomiting. One 
additional patient, who required RBC transfusions 
for the anemia secondary to myeloma, showed a 
significant rise in the hemoglobin and did not re- 
quire any more blood transfusions while receiving 
Aclacinomycin A even though there was no change 
in the M-component. 
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Toxicity 
The major dose-limiting toxicities were severe 
nausea, vomiting and myelosuppression. The me- 
dian nadir white count was 1900/mm 3 (range, 
500-6600/mm 3) and the median nadir platelet 
count was 60,000/mm 3 (range, 13,000-250,000/ 
mm3). Twenty percent of patients experienced 
either severe leukopenia or life-threatening infec- 
tion. Gastrointestinal toxicity and myelosuppres- 
sion resulted in delay of scheduled treatments in 
about 30~ of our patients. There was no evidence 
of phlebitis, skin or mucous membrane toxicity. 
Alopecia was difficult to evaluate due to incom- 
plete reporting because some of the patients had 
alopecia from prior therapy. There were no drug- 
induced deaths. Out of eight patients who received 
therapy longer than three months, no congestive 
heart failure or cardiomyopathy was observed. The 
PR patient who received a cumulative dose of 
aclacinomycin of 2400 mg/M 2 developed atrial and 
ventricular ectopic beats responded to disopyra- 
mide phosphate. The arrhythmia resolved after the 
drug was discontinued. 
Discussion 
It is difficult to evaluate the antitumor activity of 
new agents for the treatment of multiple myeloma, 
since multiple agents are commonly used for induc- 
tion, leading to multiple drug resistance. In this 
phase II study, Aclacinomycin A exhibited only a 
2.3O7o objective partial response rate, and a 4.6O7o 
clinical improvement in heavily pretreated patients. 
The number of  patients not previously treated with 
doxorubicin is too small to allow analysis as a sub- 
group. However, it should be noted that three pa- 
tients who did respond had received prior doxoru- 
bicin. Forty percent of the patients experienced 
significant delay in their planned treatments, sec- 
ondary to myelosuppression. Only seven patients 
with stable disease while on therapy were able to 
continue the treatment longer than three months. 
Since the total planned dosage is similar to that 
used in the Japanese study reported by Sezaki [3], 
it is important to compare the two studies, taking 
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into account the different administration schedules 
and response criteria. In their study, patients 
received Aclacinomycin A by IV infusion at a dai- 
ly dose of 15-25 mg/m 2 for 7 days every three 
weeks. Fifty-five percent (5 of 9) of those pre- 
viously treated responded (reduction of M-protein 
25~ - > 50%). Of these, only one would be consi- 
dered a partial remission using our criteria. It 
should be noted that the Japanese administration 
schedule allowed the delivery of the same amount 
of drug in a shorter time with less toxicity. Another 
phase II study in acute leukemia using chronic daily 
IV administration of 15 mg/M 2 to the point of 
maximum tolerable amount had shown 38% com- 
plete remission in untreated patients and 17% com- 
plete remission in previously treated group [5]. In- 
creasing response rate was also noted in patients 
who received a total dose of more than 200-300 
mg/M 2. 
In our study, aclacinomycin exhibited only mini- 
mal activity. However, the patient population had 
been heavily exposed to multiple drugs, and the 
planned treatment schedule was clinically very 
difficult to maintain. If  future trials using this drug 
are to be considered, a chronic daily schedule as 
reported by Sezaki and Yamada [3,5] should be uti- 
lized. However, with such a schedule, hospitaliza- 
tion and prolonged supportive care during myelo- 
suppression would likely be required. The higher 
response rate in a recent study using continuous in- 
fusion of vincristine, adriamycin and oral high dose 
Dexamethasone also made it attractive to study the 
continuous schedule in addition to chronic daily IV 
infusion for 1 hour, since it appeared to produce 
greater cell kill and allowed larger dose to be deliv- 
ered with less toxicity [6]. Increasing the duration 
of infusion may also reduce nausea and vomiting 
seen with IV bolus. 
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